Together, these data demonstrated that targeting MAP3K19 using a small-molecule approach therapeutically reduced pulmonary fibrosis in a humanized C.B-17SCID/bg mouse model of IPF. Here, MAP3K19 is linked to idiopathic pulmonary fibrosis.